MMP9 and schwannoma: Finally, to assess the therapeutic potential of MMP9 inhibitors in vivo, mice bearing subcutaneous schwannoma allografts were treated with silvestrol (1.5 mg/kg or 3 mg/kg) or MMP9-IN-I (3 mg/kg).